In Vitro Effects of Solubilized HLA-DR--Role in Immunoregulation?

Claus, Renate; Hausmann, Stefan; Zavazava, Nicholas; Walzel, Hermann; Schulze, Hans-Arthur; Köhler, H.; Friemel, H; Müller-Ruchholtz, W

doi:10.1006/cimm.1994.1139

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that sHLA-I molecules are produced by T and B lymphocytes [23]. Dendritic cells and macrophages, lymphocytes, and endothelial and epithelial cells can be sources of sHLA-II proteins [12]. These cells under the conditions of chronic inflammation in COPD patients are in a permanently activated state.…”

Section: Discussionmentioning

confidence: 99%

“…These proteins are involved in the interaction of all types of immune cells of the body, recognition of both their own, including modified ones, and foreign cells. HLA molecules can simultaneously be present both in a membrane-bound form on the cell surface and in a soluble form in various biological fluids [11, 12]. Soluble HLA proteins are formed by the proteolytic shedding of membrane proteins and/or by an alternative splicing of matrix RNA.…”

Section: Introductionmentioning

confidence: 99%

“…Significant amounts of sHLA-I and sHLA-II molecules are produced by various activated cells of the immune system under the influence of mitogens and various antigens [12–14]. Thus, the content of sHLA-I and sHLA-II can reflect the functional state of cellular immunity.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Soluble HLA-I and HLA-II Molecules Are Potential Prognostic Markers of Progression of Systemic and Local Inflammation in Patients with COPD

Kubysheva

Soodaeva²,

Novikov

et al. 2018

Disease Markers

View full text Add to dashboard Cite

Soluble molecules of the major histocompatibility complex play an important role in the development of various immune-mediated diseases. However, there is not much information on the participation of these proteins in the pathogenesis of chronic obstructive pulmonary disease (COPD). The aim of our work was to determine the content of soluble molecules of the major histocompatibility complex of classes I and II (sHLA-I and sHLA-II) in the exhaled breath condensate (EBC) and in the blood serum in patients with moderate to severe COPD during the exacerbation and stable phase. We investigated 105 patients (male) with COPD aged 46–67 and 21 healthy nonsmoking volunteers (male) comparable in age. The content of sHLA-I and sHLA-II molecules was studied using ELISA. We found an increase in the level of sHLA-I and sHLA-II molecules in EBC, as well as an enhancement in the serum content of sHLA-II in all the examined COPD patients compared to healthy nonsmoking volunteers. The revealed negative correlation between the serum concentration of sHLA-II and values of FEV1 and FEV1/FVC in all examined patients with COPD gives a possibility to consider the content of these proteins as an additional systemic marker of disease severity. The maximum endobronchial and serum concentrations of sHLA-I and sHLA-II were detected in patients with severe COPD during the exacerbation. The negative associations between the content of these molecules in EBC and serum and the parameters of lung function in patients with severe COPD were established. These findings suggest a pathogenetic role of sHLA-I and sHLA-II molecules in the mechanisms of the development and progression of local and systemic inflammation in COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble HLA-I and HLA-II Molecules Are Potential Prognostic Markers of Progression of Systemic and Local Inflammation in Patients with COPD

Kubysheva

Soodaeva²,

Novikov

et al. 2018

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Less is known about agonistic signaling of antibodies against HLA II molecules. In antigen-presenting cells, HLA-DR ligation by antibodies mimics TCR engagement, and induces cell activation and proliferation ( 55 – 59 ). Endothelial cells expressing HLA-DR also respond to anti-HLA-DR antibodies by increased allostimulation of T cells ( 60 , 61 ).…”

Section: Diversity Of Effector Functions Among Igg Subclassesmentioning

confidence: 99%

Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation

2016

View full text Add to dashboard Cite

Long-term outcomes in solid organ transplantation are constrained by the development of donor-specific alloantibodies (DSA) against human leukocyte antigen (HLA) and other targets, which elicit antibody-mediated rejection (ABMR). However, antibody-mediated graft injury represents a broad continuum, from extensive complement activation and tissue damage compromising the function of the transplanted organ, to histological manifestations of endothelial cell injury and mononuclear cell infiltration but without concurrent allograft dysfunction. In addition, while transplant recipients with DSA as a whole fare worse than those without, a substantial minority of patients with DSA do not experience poorer graft outcome. Taken together, these observations suggest that not all DSA are equally pathogenic. Antibody effector functions are controlled by a number of factors, including antibody concentration, antigen availability, and antibody isotype/subclass. Antibody isotype is specified by many integrated signals, including the antigen itself as well as from antigen-presenting cells or helper T cells. To date, a number of studies have described the repertoire of IgG subclasses directed against HLA in pretransplant patients and evaluated the clinical impact of different DSA IgG subclasses on allograft outcome. This review will summarize what is known about the repertoire of antibodies to HLA and non-HLA targets in transplantation, focusing on the distribution of IgG subclasses, as well as the general biology, etiology, and mechanisms of injury of different humoral factors.

show abstract

High Concentration of Soluble HLA-DR in the Synovial Fluid: Generation and Significance in “Rheumatoid-like” Inflammatory Joint Diseases

Claus

Bittorf²,

Walzel³

et al. 2000

Cellular Immunology

View full text Add to dashboard Cite

In Vitro Effects of Solubilized HLA-DR--Role in Immunoregulation?

Cited by 9 publications

References 0 publications

Soluble HLA-I and HLA-II Molecules Are Potential Prognostic Markers of Progression of Systemic and Local Inflammation in Patients with COPD

Soluble HLA-I and HLA-II Molecules Are Potential Prognostic Markers of Progression of Systemic and Local Inflammation in Patients with COPD

Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation

High Concentration of Soluble HLA-DR in the Synovial Fluid: Generation and Significance in “Rheumatoid-like” Inflammatory Joint Diseases

Contact Info

Product

Resources

About